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Over expression of endothelin (ET) and its receptors ETA and ETB
results in pathological changes including hypertrophy and ﬁbrosis. These
changes are hallmarks of conditions such as pulmonary arterial
hypertension (PAH). Dual, but not single (ETA) endothelin receptor
antagonists (ERAs), have been shown to improve survival in animal
models of pulmonary hypertension and chronic heart failure. Hyper-
stimulation of ETB receptors following ETA receptor blockade by single
ERAs leads to increased vascular permeability and ﬂuid retention. These
observations support the rationale that dual receptor antagonism may
have optimal efﬁcacy andminimized risk of edema.Macitentan is a novel
dual ERA designed for optimized physicochemical properties, favoring
sustained receptor binding and enhanced tissue penetration. Macitentan
does not increase bile salts, the proposed underlying mechanism for
elevated liver enzymes observed with the dual ERA bosentan.
Macitentan was studied in the Phase III SERAPHIN trial, the ﬁrst event-
driven, outcome trial in PAH. The study included over 740 patients.
Macitentan 10 mg reduced the risk of morbidity and mortality by 45%
versus placebo. Moreover, there was no difference in incidence of
peripheral edema or liver enzyme elevations between placebo and ma
citentan-treated patients. Current preclinical and clinical research on the
ET systemhighlights the potential for dual ERAs in other diseases. Future
directions may include the ﬁelds of scleroderma, pulmonary ﬁbrosis,
heart diseases and oncology.
doi:10.1016/j.lfs.2013.12.109
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Systemic sclerosis (SSc) is a connective tissue disease involving
tissue ﬁbrosis and endothelial injury. In the 1990s, several studies
indicated that plasma endothelin (ET )-1 was elevated in patients
with SSc, which might contribute to endothelial injuries (i.e.:
Raynaud's phenomenon, digital ulcer, pulmonary hypertension, renal
dysfunction). Interestingly, ET-1 exerted a ﬁbrotic effect inducing
collagen production in skin ﬁbroblasts, suggesting that ET-1 might be
involved in both tissue ﬁbrosis and endothelial injury in patients
with SSc. Digital ulcer in patients with SSc results from peripheral
vascular damage which related to an excessive vasoconstriction. That
may be refractory for the treatment with any prostanoids. The ability
of vasodilation in prostanoids could be almost equivalent to that in
endothelin receptor antagonist (ERA). However, prostanoids could
not exhibit anti-ﬁbrotic properties, which may be different from the
effects of ERA. In this session, I am going to show the effects of
bosentan on digital ulcers in patients with SSc and to evaluate the
inhibitory effects of bosentan on the ﬁbrogenic responses through
TGF-β in SSc ﬁbroblasts.
doi:10.1016/j.lfs.2013.12.110
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